ArticleRespiratory medicine case reports2026
Nintedanib induces rapid remission of steroid-resistant pulmonary fibrosis in an immunocompromised patient with recurrent COVID-19: A case report.
Article in Respiratory medicine case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-COVID-19 lung fibrosis is often treated empirically with corticosteroids; however, established therapeutic options for steroid-resistant cases are lacking. We report the case of a 53-year-old immunocompromised man, with a history of treatment for mantle cell lymphoma, who developed recurrent COVID-19 pneumonia. Despite an initial response to remdesivir and dexamethasone, he experienced six episodes of pneumonia over eight months. This resulted in progressive, steroid-resistant lung fibrosis requiring home oxygen therapy (HOT). Following hospitalization for severe respiratory failure, nintedanib was initiated. A rapid clinical improvement was observed, with decreased oxygen requirements and improved radiological findings within two weeks. After two months of nintedanib therapy, the patient's lung fibrosis had markedly resolved, and he was successfully weaned off HOT. Nintedanib may be an effective therapeutic option for progressive, steroid-resistant lung fibrosis that develops in the context of recurrent or persistent COVID-19, especially in immunocompromised patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.